Health science center to start anti-Prostate Cancer clinical trials
Photo by Richard Kidger
Sunnybrook Health Sciences Centre is starting a new clinical trial of Intermittent Androgen Deprivation Therapy With or Without Stereotactic Body Radiotherapy for Molecularly Identified Hormone Sensitive Oligometastatic Prostate Cancer.
This study is evaluating whether adding stereotactic radiotherapy (a new, more focused type of radiotherapy) to treat all the tumours that are present will improve outcomes or not compared to drugs alone for patients who are negative on conventional imaging and positive on PSMA PET scan.
The clinical trial started in October 27, 2020 and will continue throughout October 2027.
Patients must meet the following criteria:
- Histologic diagnosis of prostate adenocarcinoma.
- ECOG performance status 0-1.
- Stage IV hormone sensitive, synchronous or metachronous oligometastatic prostate cancer as detected by PSMA PET-CT scan with no metastases visible on conventional imaging performed within 3 months of starting ADT.
- Up to a maximum of 3 PSMA avid areas of metastatic disease.
There are other additional inclusion criteria.
Proportion of eligible patients who enroll onto the study is primary outcome measure.
Odette Cancer Centre (Toronto, Ontario, Canada, M4N3M5) is recruiting location.
Sunnybrook Health Sciences Centre (SHSC) is an academic health science centre located in Toronto, Ontario, Canada. It is the largest trauma centre in Canada. Sunnybrook is a teaching hospital, fully affiliated with the University of Toronto.
For more details: https://ichgcp.net/clinical-trials-registry/NCT04619069.
